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Abstract 
Background: Haematoxylin and eosin (H&E)—which respectively stain nuclei blue and other cellular and stromal 
material pink—are routinely used for clinical diagnosis based on the identification of morphological features. A richer 
characterization can be achieved by laser capture microdissection coupled to mass spectrometry (LCM-MS), giving 
an unbiased assay of the proteins that make up the tissue. However, the process of fixing and H&E staining of tissues 
provides challenges with standard sample preparation methods for mass spectrometry, resulting in low protein yield. 
Here we describe a microproteomics technique to analyse H&E-stained, formalin-fixed paraffin-embedded (FFPE) 
tissues.
Methods: Herein, we utilize heat extraction, physical disruption, and in column digestion for the analysis of H&E 
stained FFPE tissues. Micro-dissected morphologically normal human lung alveoli (0.082 mm3) and human lung blood 
vessels (0.094 mm3) from FFPE-fixed H&E-stained sections from Idiopathic Pulmonary Fibrosis (IPF) specimens (n = 3 
IPF specimens) were then subject to a qualitative and then quantitative proteomics approach using BayesENprot-
eomics. In addition, we tested the sensitivity of this method by processing and analysing a range of micro-dissected 
human lung blood vessel tissue volumes.
Results: This approach yields 1252 uniquely expressed proteins (at a protein identification threshold of 3 unique 
peptides) with 892 differentially expressed proteins between these regions. In accord with prior knowledge, our 
methodology approach confirms that human lung blood vessels are enriched with smoothelin, CNN1, ITGA7, MYH11, 
TAGLN, and PTGIS; whereas morphologically normal human lung alveoli are enriched with cytokeratin-7, -8, -18, 
-19, 14, and -17. In addition, we identify a total of 137 extracellular matrix (ECM) proteins and immunohistologically 
validate that laminin subunit beta-1 localizes to morphologically normal human lung alveoli and tenascin localizes to 
human lung blood vessels. Lastly, we show that this micro-proteomics technique can be applied to tissue volumes as 
low as 0.0125 mm3.
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Background
Mass spectrometry (MS) proteomics is a powerful tool 
to systemically identify and quantify proteins in complex 
biological samples. The utility of this method is maxi-
mized when performed with spatial resolution to report 
on the composition and function of specific regions of tis-
sue. Extracellular matrix (ECM) is particularly important 
in determining cell behaviour in health and disease [1] 
but is especially challenging for proteomic analysis given 
the extensive covalent crosslinking and low solubility of 
many ECM proteins [2]. However, common protocols for 
bottom-up proteomics (i.e. based on detection of peptide 
protein fragments) require sample homogenization and 
digestion, resulting in a loss of any information regarding 
protein localization and spatial relationships. To this end, 
laser capture microdissection coupled to mass spectrom-
etry (LCM-MS) is a method currently being optimized 
for microproteomics to determine regional tissue differ-
ences [3]. LCM-MS has been performed using fresh [4], 
flash-frozen [5–7], and formalin-fixed paraffin-embed-
ded (FFPE) tissues [8–11]. In this study, we describe and 
examine the performance of a protocol for LCM-MS 
analysis of FFPE sections of human lung tissue that were 
haematoxylin and eosin (H&E) stained.
H&E staining provides critical morphological char-
acterization enabling researchers to identify anatomi-
cal features of interest. However, haematoxylin staining 
has been shown to reduce protein detection by MS [12]. 
Using H&E-stained frozen tissue (not FFPE), groups have 
been able to develop highly-sensitive microproteomic 
techniques to detect 1500 to 1824 unique proteins from 
laser capture microdissected brain tissues with volumes 
as low as 3.8–6.0 × 10−4  mm3 [13, 14]. A limitation to 
translational studies is that clinical specimens are widely 
stored as FFPE tissue blocks. As a result, few LCM-MS 
studies exist for H&E-stained FFPE tissue sections. In 
an earlier study, up to 866 proteins [15] were identified 
from H&E stained FFPE sections of human head and 
neck squamous cell carcinomas; and up to 714 unique 
proteins from cutaneous squamous cell carcinoma H&E 
stained FFPE tissue [16]. This sensitivity gap supports the 
need for novel LCM-MS protocols for H&E stained FFPE 
tissues.
Herein, we describe and demonstrate the application 
of a protocol for microproteomics that combines multi-
ple steps that have been shown to individually enhance 
protein yield. First, we perform a detergent-based heat-
retrieval procedure which enhances protein solubility by 
reversing chemical crosslinking caused by fixation [17–
19]. We combined this with two techniques to enhance 
extraction of extracellular matrix (ECM) proteins: physi-
cal disruption [10, 20] and chemical extraction with a 
urea-based buffer [21]. These steps reflect the importance 
of ECM as modulators of fibrosis and cancer [22, 23]. 
Lastly, we utilize an in-column trypsin-digest system (a 
recently commercialized product, SuspensionTrap [24, 
25]) shown to increase peptide yields [12] while effec-
tively removing detergents and contaminants from the 
samples [26]. Our data analysis suggests that our protocol 
may delineate between cellular and ECM protein com-
ponents characteristic of the different regions of FFPE 
H&E-stained tissue.
Materials and methods
Procurement of human lung tissue
The use of human lung tissue was approved by University 
of Manchester Health Research Authority with patient 
consent under protocol REC#14/NW/0260. The speci-
mens used for this study met the criteria for Idiopathic 
Pulmonary Fibrosis (IPF) diagnosis [27], however, we 
used distal lung tissue that appeared morphologically 
normal for the LCM-MS study.
Immunohistochemistry
Human lung samples were formalin-fixed and paraf-
fin-embedded (FFPE). Deparaffinized and rehydrated 
5-micron sections were subjected to antigen heat 
retrieval using citrate buffer (Abcam, ab208572), for 
30 min at 100 °C, cooled to room temperature for 20 min, 
treated with 3% hydrogen peroxide for 5  min, blocked 
in TBS Super Block for 1 h (Thermo Fisher; 37581), and 
probed with primary antibody (TNC, 1:500, Abcam, 
ab108930; LAMB1, 1:1000, Abcam, ab16048) over-
night in 10% blocking solution. The following day, the 
specimens were subjected to Novolink Polymer Detec-
tion Systems (Leica RE7270-RE, per the manufactur-
er’s recommendations), developed for 5  min with DAB 
Chromagen (Cell Signal, 11724), counterstained with 
haematoxylin and cover-slipped with Permount (Thermo 
Fisher Scientific, SP15).
Pentachrome staining
We followed a modified Russell-Movats pentachrome 
staining protocol. Deparaffinized specimens were stained 
with alcian blue for 20  min (1% alcian blue [Sigma-
Aldrich, A-1986] and 1% glacial acetic acid), treated in 
Conclusion: Herein we show that our multistep sample preparation methodology of LCM-MS can identify distinct, 
characteristic proteomic compositions of anatomical features within complex fixed and stained tissues.
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alkaline alcohol for 1  h (90% alcohol and 10% of a 30% 
ammonium hydroxide solution [Sigma-Aldrich, 221228]), 
alcohol haematoxylin solution for 10  min (50% of a 5% 
absolute alcoholic haematoxylin [Sigma Aldrich, P4006], 
25% of a 10% aqueous ferric chloride [Sigma-Aldrich, 
F2877], and 25% of 2 grams Iodine [Alfa Aesar, A12278], 
4 grams potassium iodide [Fluorochem, 319032] in 
100 mL water), 5% aqueous sodium thiosulfate for 1 min 
(Sigma-Aldrich, S-6672), and then crocein scarlet-acid 
fuchsin solution for 2 min (4 parts crocein scarlet—0.1% 
crocein scarlet [Alfa Aesar, J66876] and 0.5% glacial acetic 
acid; 1 part acid fuchsin—0.1% acid fuchsin [Alfa Aesar, 
B22222] and 0.5% glacial acetic acid). Sections were then 
treated 2 times with 5% phosphotungstic acid for 5 min 
each (Sigma Aldrich, P4006), washed 3 times with 100% 
alcohol, stained with 6% alcoholic saffron (VWR, 283-
295-0) for 15 min, and then coverslipped with Permount.
Haematoxylin and eosin staining
5-micron FFPE sections were mounted onto MMI 
membrane slides (MMI, 50102) and stained using an 
automated stainer (Leica XL) at the Histology Core at 
University of Manchester. In short, the FFPE slides were 
dewaxed by xylene and alcohol treatment, followed by a 
2-minute hematoxylin incubation, acid alcohol treated, 
and stained with eosin for 1 min. Slides were then washed 
in 100% ethanol and allowed to air dry. Slides were then 
stored in 4 °C for up to 1 week before LCM-MS.
Histological imaging
Stained slides were imaged using a DMC2900 Leica cam-
era along with Lecia Application Suite X software (Leica).
Laser capture microdissection
The 5-micron H&E slides were loaded onto the MMI 
CellCut Laser Microdissection system (Molecular 
Machines & Industries). Using MMI CellCut software, 
we performed a complete slide scan using a CellScan 
toolbar at 4× magnification to make navigation easier. 
Using a computer mouse, we used a closed-shape man-
ual drawing tool to select our region of interest. We then 
focused our laser at 350 μm and performed an automated 
cutting using a 60% laser power setting moving at 50 μm/
sec. To collect microdissected specimens, we used adhe-
sive MMI transparent caps (MMI, 50204) and MMIs 
CapLift technology to gently lift and store specimens 
onto the adhesive caps. Captured specimens were stored 
at − 20  °C for several weeks until all samples were col-
lected and processed for mass spectrometry.
Sample preparation for mass spectrometry
Laser microdissected tissue was resuspended in 25  μL 
50  mM triethylammonium bicarbonate (TEAB) (Sigma, 
T7408), 5% SDS (pH 7.5) and subjected to 95  °C for 
20  min, then 60  °C for 2  h while shaking at 1400 RPM 
(Eppendorf, ThermoMix C). We then added 75  μL of a 
50 mM TEAB, 5% SDS, 10 M urea, 13.3 mM DTT (pH 
7.5) solution to the 25 μL sample, after it had cooled to 
room temperature to avoid deamination, to create a final 
volume of 100 μL of 50 mM TEAB, 5% SDS, 7.5 M urea, 
10  mT DTT (pH 7.5). Samples were then placed into a 
Covaris microtube (Covaris, 520045) and sheared using 
the LE220-Plus Focused Ultrasonicator (Covaris, UK) 
set at 6  °C with the following settings: duration of 50  s, 
peak power 500, duty factor of 20.0%, cycles/burst of 200, 
average power at 100, and then delayed for 10 s. This was 
repeated for a total of 10 cycles (10-min total run time). 
The homogenization process resulted in the break-up of 
bulk pieces of tissue, leaving only a fine suspension of 
material. A benefit of the LE220-Plus Focus Ultrasonica-
tor is that it allows for the processing of up to 96 samples 
in parallel in a single run. After shearing, samples were 
alkylated by the addition of 8 µL of 500 mM iodoaceta-
mide (Sigma, I1149) and incubated for 30 min in the dark. 
Samples were then acidified by the addition of 12 μL of 
12% aqueous phosphoric acid (Sigma, 345245) and cen-
trifuged at 12000 RPM for 5  min. The supernatant was 
collected and resuspended with 600 µL of 90% methanol, 
100 mM TEAB (pH 7.10). The sample was then added to 
a micro S-Trap column (ProtiFi, C02-micro) and centri-
fuged at 2000 RPM using 200 µL at a time until all the 
sample had passed through the column. After discarding 
the flow through, the S-Trap column was washed by add-
ing 150  μL of 90% methanol, 100  mM TEAB (pH 7.10) 
and centrifuging at 2000 RPM. Washing was repeated a 
further 9 times, discarding the flow through each time. 
In-column digest was performed by adding 25  μL of a 
0.8  µg/µL trypsin solution (proteomics grade trypsin; 
Promega, V5111) in 50  mM TEAB pH 8.0 in accord-
ance with the manufacturer’s protocol for 1-hour diges-
tion. Trypsin digestion was performed at 47  °C for 1  h 
without shaking. Samples were eluted by adding 40  μL 
of 50 mM TEAB (pH 8.0) and centrifuging at 2000 RPM, 
followed by the addition of 40 μL of 0.2% aqueous formic 
acid (Sigma Aldrich, 27001) and centrifuging, and finally 
adding 40  μL 50% aqueous acetonitrile (Fisher, A955-
212) and centrifuging. Eluted fractions were combined 
and the total 120 μL sample was then lyophilised using a 
speed-vac (Heto Cooling System).
Desalting of samples was performed using Oligo R3 
resin beads. Briefly, 100 µL of a 10 mg/mL settled Oligo 
R3 resin (Thermo Scientific, 1-1339-03) in aqueous 50% 
acetonitrile was placed into a 96-well 0.2 µm PVDF filter 
plate (Corning, 3504). The plate was centrifuged at 1400 
RPM (Thermo Scientific, Megafuge 16) for 1 min to clear 
Oligo R3 resin with a blank 96-well plate underneath to 
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catch the flow through which was then discarded. 100 μL 
of aqueous 50% acetonitrile was mixed with the resin and 
centrifuged again, discarding the flow through. Finally, 
100 μL of aqueous 0.1% formic acid were mixed with the 
resin and centrifuged for a total of two repeats, while 
discarding the flow through. Samples were then resus-
pended in 100  µl of aqueous 5% acetonitrile, 0.1% for-
mic and mixed with the now washed Oligo R3 Resin and 
allowed to shake on a plate shaker (Eppendorf, Thermo-
mixer Comfort) for 5 min at 800 RPM, and then centri-
fuged (flow through was discarded). The sample peptides 
were now bound to the Oligo R3 Resin and washed for 
a total of ten times by the addition of 100 µL of aqueous 
0.1% formic acid, mixed for 2  min at 800 RPM, centri-
fuged, and flow through discarded. Finally, the washed 
peptides were eluted by mixing with 50 µL of aqueous 
50% acetonitrile for 2 min at 800 RPM, centrifuged, col-
lecting the flow through in a clean 96-well capture plate. 
Elution was repeated with an additional 50  μL of aque-
ous 50% acetonitrile and retained. Desalted peptides 
were lyophilized in a speed-vac and stored at 4  °C until 
needed.
Liquid chromatography coupled tandem mass 
spectrometry
Lyophilized peptides were resuspended in 10 μL of a 5% 
acetonitrile, 0.1% formic acid solution and evaluated by 
liquid chromatography (LC) coupled tandem MS (LC-
MS/MS) using an  UltiMate® 3000 Rapid Separation LC 
system (RSLC, Dionex Corporation, Sunnyvale, CA) 
coupled to a Q Exactive HF mass spectrometer (Thermo 
Fisher). To maximize the sensitivity of the system, it was 
configured to directly inject onto the analytical column 
(temperature set at 35  °C) without a trap. Mobile phase 
A was 0.1% formic acid in water and mobile phase B was 
0.1% formic acid in acetonitrile and the column used was 
a 75 mm × 250 μm i.d. 1.7 µM CSH C18, analytical col-
umn (Waters). The analytical method used was as follows: 
a 1  μL aliquot of the sample (i.e. 10% of the total pep-
tides) was transferred to a 5 μL injection loop to increase 
the amount of sample analyzed at a flow rate of 300 nL/
min for 5  min at 5% B. The loop was then taken out of 
line and the peptides were separated using a gradient that 
went from 5% to 7% B at 200 nL/min in 1 min, followed 
by a shallow gradient from 7% to 18% B in 64 min, then 
from 18% to 27% B in 8 min, and finally from 27% to 60% 
B in minute. At 85 min, the flow is increased to 300 nL/
min until the end of the run at 90 min.
Mass spectrometry data was acquired in a data directed 
manner for 90  min in positive mode. Peptides were 
selected for fragmentation automatically by data depend-
ent analysis on a basis of the top 12 peptides with m/z 
between 300 and 1750Th and a charge state of 2, 3 or 4 
with a dynamic exclusion set at 15 s. The MS Resolution 
was set at 120,000 with an automatic gain control (AGC) 
target of 3e6 and a maximum fill time set at 20 ms. The 
MS2 Resolution was set to 30,000, with an AGC target of 
2e5, a maximum fill time of 45 ms, isolation window of 
1.3Th and a collision energy of 28.
Mass spectrometry data analysis and statistics
Raw spectra were automatically aligned using Progen-
esis QI for proteomics (version 4.1; Nonlinear Dynam-
ics, Waters). Progenesis QI’s alignment feature allows 
MS2 spectral information to be shared across samples so 
that MS1 spectra that do not have associated MS2 spec-
tra in a given sample (owing to low abundance and thus 
not being selected for fragmentation in data-dependent 
acquisition) can still be identified. Alignment decreases 
the number of missing values (a common problem in 
proteomics) at the risk of wrongly inferring presence of 
a peptide when it may genuinely be absent. Spectra from 
different tissue sections (human lung blood vessel or 
morphologically normal human lung alveoli) were ana-
lysed either separately (with alignment between donors 
but not between sections; Fig. 2) or together (with align-
ment between both sections and donors; Fig.  3). Peak-
picking in Progenesis QI was performed using default 
parameters which include charges from + 1 to + 4 (an 
inclusion useful for downstream troubleshooting) and 
subsequent features were then filtered to leave only pep-
tides with a charge of + 2 and + 3, with 3 or more iso-
topes. Remaining features were searched using Mascot 
(server version 2.5.1, parser version 2.5.2.0; Matrix Sci-
ence), against the SwissProt and TREMBL human data-
base. The peptide database was modified to search for 
alkylated cysteine residues (monoisotopic mass change, 
+57.021  Da) as a fixed modification, with oxidized 
methionine (+ 15.995  Da), hydroxylation of asparagine, 
aspartic acid, proline or lysine (+ 15.995  Da) and phos-
phorylation of serine, tyrosine, threonine (+ 79.966  Da) 
as variable modifications. A maximum of two missed 
cleavages was allowed. Peptide tolerance and MS/MS 
tolerance were set to 8  ppm and 0.015  Da, respectively. 
Peptide detection intensities were exported from Progen-
esis QI as comma separated variable (.csv) spreadsheets 
for further processing. Peptides assigned to proteins with 
‘unreviewed’ status in the UniProt database were reas-
signed to the most abundant ‘reviewed’ protein with 
sequence identity in the dataset. Peptides shared between 
different protein groups were excluded from subsequent 
analysis. For differential expression analysis in Fig.  3, 
fold changes were calculated using the Matlab (version 
2015a; The MathWorks) implementation of BayesENpro-
teomics [28], available from: https ://githu b.com/VenkM 
allik arjun /Bayes ENpro teomi cs. BayesENproteomics fits 
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regularized regression models to take into account donor 
variability and variable behaviour of peptides assigned to 
a single protein group (due to post-translational modifi-
cations or differential splicing), weighting observations 
based on confidence in peptide identification (inferred via 
Mascot scores). These features allow BayesENproteomics 
to calculate fold changes for the dominant proteoforms 
of proteins represented in a complex clinical dataset. 
Missing values were imputed within BayesENproteom-
ics model fitting using an adaptive multiple imputation 
method that attempts to discern whether a given miss-
ing value is missing at random (MAR) or non-randomly 
(MNR) and imputes from appropriate distributions [28]. 
Reactome [29, 30] Pathway enrichment analysis was per-
formed as described in [28], by fitting linear models for 
each pathway represented in the dataset, based on pro-
tein-level fold changes calculated as described above.
Tissue titration data analysis
Samples were loaded to the MS as described above. To 
restrict carryover of the previous sample, we loaded the 
MS with the lowest tissue volume sample first followed by 
increasing tissue volume samples. Raw spectra were pro-
cessed using MaxQuant (version 1.6.10.43) [31] against 
the human proteome obtained from Uniprot (March 
2020) [32]. Default settings were used with variable mod-
ifications as methionine oxidation and N-terminal acety-
lation, fixed modification of carbamidomethylation of 
cysteine and match between runs was selected to allow 
MS/MS identifications to be transferred across samples.
Data availability
Raw mass spectrometry data were deposited to Pro-
teomeXchange with the identifier PXD014762.
Results
Microproteomics for haematoxylin & eosin‑stained 
formalin‑fixed paraffin‑embedded tissue
Morphologically normal human lung alveoli and human 
lung blood vessels were laser microdissected from unin-
volved IPF tissue (Fig.  1a) using a pentachrome and 
H&E stain as a guide. Per specimen (n = 3 IPF patients), 
approximately 0.082  mm3 of morphologically normal 
human lung alveoli and 0.094 mm3 of human lung blood 
vessels were pooled from H&E-stained 5-micron FFPE 
sections and used for downstream mass spectrometry; 
encompassing a total of 6 LCM-MS samples (Schematic 
in Fig.  1b). In short, samples were resuspended in 5% 
SDS, and heated to denature proteins, then resuspended 
at room temperature to a final solution of 7.5  M urea, 
5% SDS, and 10  mM DTT to enhance ECM solubility 
[21]. Samples were then sheared using a LE220 focused-
ultrasonicator; a 96-multiwell system which allows for 
scalability (Covaris Ltd, United Kingdom). This com-
bined protocol extracted more proteins as assessed by 
SDS-PAGE than individual methods (Additional file  1: 
Figure. S1). Samples were then placed into an S-Trap col-
umn (ProtiFi, NY, USA) [25], desalted, and analysed for 
mass spectrometry.
The ECM comprising morphologically normal human lung 
alveoli and blood vessels
We first performed a qualitative analysis of our data 
using Progenesis QI (Nonlinear Dynamics) and Mascot 
(Matrix Science). With a cut-off of 3 or more peptides, 
we identified 1107 and 683 proteins in morphologically 
normal human lung alveoli and human lung blood ves-
sels, respectively (Fig.  2a). We then used the Human 
Matrisome Project (http://matri somep rojec t.mit.edu) 
which provides a list of core matrisome proteins (ECM 
glycoproteins, collagens, and proteoglycans) and matri-
some-associated proteins (ECM-affiliated proteins, ECM 
regulators, and secreted factors) and directly compared 
to our protein list [33]. This analysis identified 106 and 
119 ECM proteins in morphologically normal human 
lung alveoli and human lung blood vessels, respectively. 
We show that 88 ECM constituents are shared within 
these tissues (Additional file  2: Table  S1), with 18 pro-
teins unique to morphologically normal human lung 
alveoli and 31 proteins unique to human lung blood ves-
sels (Fig. 2b). This approach utilizes multi-steps to enrich 
for ECM proteins and we report that 11.1% of the pro-
teins detected are ECM components. This is in accord 
with studies utilizing human lung specimens where the 
percentage of ECM components detected are reported 
as 5.4% [34], 7.2% [35], and 8.2% [36]; in mouse lungs, 
5.2% is reported [37]. The protein gene names for these 
regions are shown in Fig. 2c. To validate these results, we 
carried out immunostaining for two proteins that prot-
eomics identified as specific to each tissue. Antibody to 
laminin subunit beta-1 (LAMB1) stained predominantly 
the alveoli (red arrows), whereas antibody to tenascin 
(TNC) stained blood vessels but not alveoli (blood vessel 
outlined in black dots; Fig. 2d).
We next used a quantitative approach to gain further 
insight into the differences in the total protein abun-
dance between morphologically normal human lung 
alveoli and human lung blood vessel. This was done by 
utilizing Progenesis QI to align all samples from differ-
ent sections together, followed by BayesENproteomics 
[28] to compare the differential expression of the 1252 
proteins identified (at a protein identification thresh-
old of 3 unique peptides). Principal component analy-
sis (PCA) on normalized peptide intensities prior to 
protein quantification showed that sample handling 
and data processing did not perturb the relationship 
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Fig. 1 Laser capture microscopy of human lung blood vessels for mass spectrometry. a Blood vessels are identified by pentachrome stain 
(red arrows) and serial sections are used to laser microdissect blood vessels and adjacent alveoli. b A workflow of tissue preparation for mass 
spectrometry. Laser captured tissue is detergent treated, subjected to heat, resuspended with Urea, sheared using Covaris, and samples are later 
placed into a S-Trap Column for trypsin digest, followed by desalting prior to mass spectrometry loading
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between samples from different tissue sections (Fig. 3a). 
Subsequent analysis of protein fold changes showed 
that 206 proteins are enriched in blood vessels whereas 
686 are enriched in morphologically normal alveoli 
(Additional file  3 Fig.  3b). In accordance with prior 
knowledge, proteins known to be expressed in blood 
vessels, such as smoothelin, CNN1, ITGA7, MYH11, 
TAGLN, and PTGIS are over-represented in the blood 
vessels (highlighted in green dots) [38–41]. The top 10 
pathways and top 10 proteins enriched in human lung 
blood vessels are shown in Tables 1 and 2, respectively. 
Similarly, cytokeratin-7, -8, -18, -19, 14, and -17 are 
enriched in the alveoli as previously shown (highlighted 
in purple dots) [42, 43]. The top 10 pathways and top 10 
proteins enriched in alveoli are shown in Tables 3 and 
4, respectively.    
We next specifically examined the core-matrisome 
(red dots) and matrisome-associated (blue dots) pro-
teins (Fig. 3c). Consistent with prior knowledge, blood 
vessels have been shown to be enriched in aggre-
can (ACAN), elastin (ELN), emilin (EMIL1), lumican 
(LUM), tenascin (TNC), von Willebrand factor (VWF), 
nidogen (NID1), and collagen VIII (CO8A2) which 
are shown in the volcano plot [44]. Similarly, ECM 
proteins MMP9, MUC1, PSPB (surfactant protein B), 
S100A8/A9, ANXA2, and collagen VI are all known 
to be enriched in lung epithelium in the context of 
IPF pathogenesis which are shown in the volcano plot 
[45–50]. Together, these data further support that our 
microproteomics protocol, using multiple techniques 
to process samples, may be useful to delineate the ECM 















Fig. 2 The ECM comprising morphologically normal alveoli and blood vessels in IPF. a–b A Venn diagram showing the number of (a) total and (b) 
ECM proteins within morphologically normal alveoli and blood vessels (n = 3 IPF specimens). c A list of ECM genes specific for morphologically 
normal alveoli and blood vessels. d Serial sections stained with H&E, anti-LamB1 and anti-TNC. A blood vessel is outlined in black dots, red arrows 
highlight intense immunostain for LamB1, and black arrow highlights immunostain for TNC within the blood vessel. Scale bar represents 100 μm
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Fig. 3 The ECM comprising morphologically normal alveoli and blood vessels in IPF. a Principal component analysis (PCA) of normalised peptide 
intensities for the micro-dissected human lung blood vessels (red) and alveoli (blue). Numbers next to dots denote donor IDs. Values in brackets 
denote percentage of variance explained by each principal component (PC). b A volcano plot of all 1252 proteins or (c) ECM proteins only showing 
a negative natural log of the FDR values plotted against the base 2 log of the change for each protein. The thresholds are set for a base log 
2 > 0.5 and FDR p value < 0.05; n = 3 IPF specimens. Purple dots indicate known proteins expressed in alveoli, green dots indicate known proteins 
expressed in blood vessels, blue dots represent matrisome-associated proteins, and red dots represent core-matrisome proteins
Table 1 Reaction pathways enriched in blood vessels
Pathway name/reactome pathway identifier (R‑HSA) Effect size FDR Set size
Collagen chain trimerization/R-HSA-8948216 2.71 1.83E−14 22
ECM proteoglycans/R-HSA-3000178 2.20 2.12E−14 36
Collagen biosynthesis and modifying enzymes/R-HSA-1650814 2.23 2.22E−11 26
Non-integrin membrane-ECM interactions/R-HSA-300171 2.36 9.69E−11 20
Molecules associated with elastic fibres/R-HSA-2129379 2.21 1.11E−10 15
Syndecan interactions/R-HSA-3000170 2.45 1.11E−10 12
Extracellular matrix organization/R-HSA-1474244 2.84 3.42E−10 10
MET activates PTK2 signaling/R-HSA-8874081 2.26 9.02E−10 15
Collagen degradation/R-HSA-1442490 2.18 3.12E−09 16
Laminin interactions/R-HSA-3000157 1.95 2.36E−08 6
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Titration of hematoxylin & eosin‑stained formalin‑fixed 
paraffin‑embedded tissue for microproteomics
We next sought to determine the sensitivity of our LCM-
MS protocol by titrating varying volumes of H&E-stained 
FFPE human lung tissue. We chose to laser capture 
microdissect human lung blood vessels at a volume of 0.1, 
0.05, 0.025, 0.0125, and 0.00625  mm3. Using Maxquant 
to process our data, we plot the volume of tissue ver-
sus number of peptide counts (using 2 unique peptides) 
(Fig. 4). Herein, we find that peptide counts are statisti-
cally decreased at our lowest volume of 0.00625 mm3 of 
FFPE H&E stained tissue, and we see a modest decrease 
in peptide counts with decreasing volume input.
Discussion
The methods described use techniques to insure sensitiv-
ity and reproducibility. The Covaris focused ultrasonica-
tion system provided a highly efficient method of sample 
disruption with a format that allows up to 96-samples to 
be processed as a batch with both the amount of energy 
applied and temperature controlled precisely. The S-Trap 
digestion method was performed in parallel and we 
found that it provided efficient sample recovery as pre-
viously reported [24, 25]. To desalt samples, we used 
POROS R3 beads as they are highly hydrophobic which 
retain hydrophilic peptides, and have a low susceptibil-
ity for clogging [51]. We found that incubating the beads 
during extraction increases recovery over tip based 
Table 2 Proteins enriched in blood vessels
Gene symbol; name Log2 fold‑change FDR
SMTN; smoothelin 5.63 1E−15
MYPT2; myosin phosphatase-targeting 
subunit 2
5.42 9.23E−13
DMD; dystrophin-1 4.78 1E−15
CNN1; calponin-1 4.73 1E−15
LMOD1; leiomodin-1 4.70 1E−15
SYUG; gamma-synuclein 4.47 1.44E−15
MYL9; myosin RLC 4.44 1.22E−15
FLNC; filamin-C 4.38 1E−15
ELN; elastin 4.32 1E−15
PTGIS; prostacyclin synthase 4.31 1.12E−14
Table 3 Reactome pathways enriched in alveoli
Pathway name/reactome pathway identifier (R‑HSA) Effect size FDR Set size
Neutrophil degranulation/R-HSA-6798695 1.06 1.83E−14 162
Regulation of expression of SLITs and ROBOs/R-HSA-9010553 0.99 1.83E−14 283
L13a-mediated translational silencing of Ceruloplasmin expression/R-HSA-156827 1.19 1.83E−14 61
Translation initiation complex formation/R-HSA-72649 1.21 1.83E−14 33
Formation of a pool of free 40S subunits/R-HSA-72689 1.20 1.83E−14 55
Formation of the ternary complex, and subsequently, the 43S complex/-HSA-72695 1.22 1.83E−14 29
Ribosomal scanning and start codon recognition/R-HSA-72702 1.20 1.83E−14 34
GTP hydrolysis and joining of the 60S ribosomal subunit/R-HSA-72706 1.18 1.83E−14 62
mRNA splicing—major pathway/R-HSA-72163 1.23 1.83E−14 42
SRP-dependent cotranslational protein targeting to membrane/R-HSA-1799339 1.23 1.83E−14 56
Table 4 Proteins enriched in alveoli
Gene symbol; name Log2 fold‑change FDR
CAH4; carbonic anhydrase 5.11 1.22E−15
ACSL5; long-chain-fatty-acid CoA ligase 5 4.50 6.11E−13
AMPE; aminopeptidase A 4.37 1.04E−09
AQP4; aquaporin-4 4.32 1.65E−14
RAGE; advanced glycosylation end product-specific receptor 4.24 7.52E−14
ABCA3; ATP-binding cassette sub-family A member 3 4.19 1.65E−14
K2C7; cytokeratin-7 4.12 1.65E−14
K1C18; cytokeratin-18 3.90 1.65E−14
PCAT1; LPC acyltransferase 1 3.80 1.65E−14
K1C19; cytokeratin-19 3.75 4.17E−05
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methods as the time for adsorption on to the beads are 
long and more regulated. The plate based format allows 
for samples to be rapidly cleaned in parallel. In addition, 
the liquid chromatography system was adjusted for sen-
sitivity and speed. To increase sensitivity, the system is 
configured for direct injection on to the analytical col-
umn (i.e. no trap column is used) with low flowrates of 
200 nl/min; In our experiences we find that this supports 
chromatographic resolution, peak capacity, signal inten-
sity, and decreases sample complexity. To increase speed, 
our experience show that using low injection volumes 
and a high loading rate of 300 nL/min supports signal 
intensity without impacting chromatograph resolution. 
To insure minimal dead volume and peak broadening, 
junctions after the column were made butt-to-butt with 
polished capillaries. Taken together, we found that these 
features improved our MS methodology.
Common proteomics-based efforts to map tissue com-
position are limited by the loss of spatial information 
caused by the need to completely homogenize tissue 
pieces during sample preparation. Here we describe a 
micro-proteomics strategy using tissue processed by the 
most widely used staining technique to identify regions 
of interest, followed by microdissection and subsequent 
proteomics. With the limitation of a small sample size 
(n = 3), we determined the ECM composition of morpho-
logically normal lung alveolar structures as compared to 
adjacent human lung blood vessels in unaffected regions 
from IPF lungs. To address the many challenges includ-
ing low tissue volumes (< 0.1  mm3), formalin-fixation, 
and histological stains, we utilized a variety of strategies 
employing commercially available tools to qualitatively 
show a yield of 1107 and 683 unique proteins to mor-
phologically normal human lung alveoli and human lung 
blood vessels, respectively, and identified a total of 137 
as ECM proteins. Using BayesENproteomics as a quan-
titative approach [28], we identify 1252 unique proteins 
with 892 differentially expressed proteins between these 
regions using a strict threshold of 3-unique peptides. 
Using 2 unique peptides as the threshold, we would iden-
tify a total of 1737 unique proteins using this approach 
(485 more proteins).
One rate limiting step to this approach is the time 
required to micro-dissect tissue. In this study, it took 
about 15  h of laser capture microscope time to capture 
both human lung blood vessels and morphologically nor-
mal lung alveoli at roughly 0.1  mm3, per patient. This 
would become a challenge if a region of interest is a small 
cell cluster which would require many sections, slides, 
and other resources to accomplish. It was therefore 
imperative to determine the sensitivity of our approach 
by titration of starting volumes and then subjecting the 
material micro-proteomics. Fortunately, we found that 
we can detect similar peptides at a starting tissue vol-
ume of 0.0125 mm3, a magnitude of volume lower than 
our initial analysis. This is a feasible working volume and 
provides researchers with a starting point to plan and 
execute similar approaches to their studies.
An emerging theme is that the ECM is a driver of dis-
ease processes including atherosclerosis [52] fibrosis 
[22, 53, 54] and cancer [23]. The strategy developed here 
could be applied to a multitude of settings where tissue 
heterogeneity is a common theme. Currently, ECM tis-
sue atlases of IPF [55] and, to an extent, liver fibrosis [56] 
have been developed to help researchers better under-
stand and model fibrosis progression. Thus, this strat-
egy could be applied to archived FFPE tissues to reliably 
determine not only regional ECM composition, but cel-
lular pathways perturbed in health and disease.
The work described here could be enhanced by the 
combination of other ‘omic’ studies. For instance, serial 
sections following laser capture microdissection could 
be used for next-generation sequencing of RNA or DNA 
[57] for a more complete profiling of the regions of inter-
est. In addition, matrix-assisted laser desorption/ioniza-
tion (MALDI) could be applied to determine gradient 
changes at defined tissue interphases [58]. A limitation to 
this study is that H&E staining relies on pattern recog-
nition rather than staining for specific proteins, however, 

























Fig. 4 Peptide counts of varying volumes of laser capture 
microdissected tissue subjected to mass spectrometry. Blood 
vessels from one IPF specimen was laser capture microdissected at 
given volumes and prepared for mass spectrometry with peptide 
counts shown (n = 1, with each condition performed in 3 technical 
replicates); ** p < 0.01 (one-way ANOVA with Tukey post hoc testing)
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optical microproteomics (STOMP) which combines anti-
bodies and fluorescence to identify regions of interest 
[59].
Conclusion
Our work is a step towards processing complex tissues 
even after formalin-fixation and hematoxylin and eosin-
staining. The application of this novel microproteomics 
protocol, using commercially available tools, will enhance 
the development of comprehensive tissue atlases for a 
variety of pathologies.
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